
OMIC
Healthcare · Medical Instruments & Supplies · $50.8M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2024
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 13, 2024 | Time not confirmed | -7.86 | -6.72 | +14.5% |
| Aug 7, 2024 | Before the open | -0.29 | -8.57 | -2855.2% |
| May 14, 2024 | After the close | -0.35 | -0.34 | +2.9% |
| Mar 18, 2024 | After the close | -0.34 | -0.32 | +5.9% |
| Nov 14, 2023 | After the close | -0.38 | -0.31 | +18.4% |
| Aug 9, 2023 | After the close | -0.37 | -0.35 | +5.4% |
| May 9, 2023 | After the close | -0.35 | -0.33 | +5.7% |
| Mar 2, 2023 | After the close | -0.43 | -0.29 | +32.6% |
| Nov 7, 2022 | After the close | -0.41 | -0.33 | +19.5% |
| Aug 9, 2022 | After the close | -0.38 | -0.34 | +10.5% |
| May 10, 2022 | After the close | -0.33 | -0.31 | +6.1% |
| Mar 2, 2022 | After the close | -0.31 | -0.27 | +12.9% |
| Nov 9, 2021 | After the close | -0.24 | -0.25 |
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and spatial multiomics technology for researchers and clinicians to advance science and medicine. It is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition…
| -4.2% |
| Aug 3, 2021 | Before the open | -0.20 | -0.43 | -115.0% |
| May 28, 2021 | After the close | — | -0.40 | — |
| Mar 31, 2021 | Time not confirmed | 0.00 | -2.05 | — |
| Mar 31, 2020 | Time not confirmed | 0.00 | -0.52 | — |